Quanterix SR-X multiplex biomarker detection system

Quanterix has expanded its single molecule array (Simoa) technology platform portfolio to include the SR-X benchtop instrument. The product uses single molecule measurements to assess previously undetectable proteins and can reduce sample volume requirements when compared to alternative approaches, according to the company — all in a benchtop format that can be easily integrated with existing automation platforms.

In addition to a small instrument footprint, the unit has been optimised for increased multiplexing capabilities, making it an easy-to-use option for high-sensitivity biomarker analysis of either proteins or nucleic acids. It is capable of measuring nucleic acids with ultrasensitivity, without utilising polymerase chain reaction (PCR).

The SR-X is part of a complete solution including a menu of more than 70 ultrasensitive protein detection assays, as well as a series of multiplex assays for critical biomarkers, including the first six-plex Simoa assay for quantitative measurement of elusive inflammatory biomarkers in the blood. Simoa technology also enables measurement of ultrasensitive nucleic acid levels, including miRNA, without utilising PCR methodologies.

Simoa’s multiplexing capabilities and digital sensitivity provide the ability to measure economically circulating clinically relevant concentrations of immunological mediators, exosomes and miRNA in a single benchtop instrument. Research has shown that the platform has the potential to detect biomarkers in the subclinical state, which is valuable in the monitoring of neurodegeneration in diseases like Alzheimer’s and multiple sclerosis.